8-K: Avidity Biosciences Acquired by Novartis, Reports Strong Q3

Avidity Biosciences announced its acquisition by Novartis for approximately $12 billion, alongside positive Q3 2025 financial results and significant clinical progress for its RNA therapeutics pipeline.

Summary

• Avidity Biosciences entered into a definitive merger agreement with Novartis AG for a total equity value of approximately $12 billion.
• Avidity expects to separate its early-stage precision cardiology programs into a new publicly traded company, 'SpinCo'.
• A clear path forward is aligned with the FDA following a pre-BLA meeting for del-zota, with BLA submission planned for 2026 for accelerated approval.
• One-year data for del-zota demonstrated sustained muscle protection, leading to meaningful improvement and reversal of disease progression across multiple key functional measures.
• The FDA granted Breakthrough Therapy designation to del-zota in July 2025.
• Enrollment for the Phase 3 HARBOR trial of del-desiran for myotonic dystrophy type 1 (DM1) was completed in July 2025.
• Topline data from the FORTITUDE biomarker cohort for del-brax for facioscapulohumeral muscular dystrophy (FSHD) is expected in the second quarter of 2026.
• The company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Collaboration revenues for the third quarter of 2025 were $12.5 million, primarily from a $10.0 million clinical development milestone under the Eli Lilly agreement.
• Net loss for the third quarter of 2025 was $174.4 million, compared to $80.4 million for the same period in 2024.
• Research and development expenses increased to $154.9 million in Q3 2025 from $77.2 million in Q3 2024, driven by advancement of clinical programs and higher manufacturing and personnel costs.
• General and administrative expenses increased to $46.3 million in Q3 2025 from $23.3 million in Q3 2024, due to higher personnel and commercial infrastructure costs.

Sentiment

Score: 9

Explanation: The definitive merger agreement with Novartis at a substantial valuation, coupled with highly positive clinical data for del-zota and FDA Breakthrough Therapy designation, represents a significant positive inflection point for the company. While operating expenses increased, this is expected for a growing biotech advancing multiple late-stage clinical programs and is overshadowed by the acquisition news.

Positives

• Definitive merger agreement with Novartis AG for approximately $12 billion, maximizing value for investors.
• Positive one-year data for del-zota in Duchenne muscular dystrophy (DMD) showing sustained muscle protection and reversal of disease progression.
• FDA granted Breakthrough Therapy designation to del-zota in July 2025, indicating significant therapeutic potential.
• Clear path forward with the FDA for del-zota's BLA submission in 2026 for accelerated approval.
• Completion of enrollment for the Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 (DM1).
• Strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, expected to fund operations to mid-2028.
• Received a $10.0 million clinical development milestone payment from Eli Lilly and Company.

Negatives

• Increased net loss of $174.4 million for Q3 2025, compared to $80.4 million for Q3 2024.
• Significant increase in research and development expenses to $154.9 million for Q3 2025, up from $77.2 million for Q3 2024.
• Substantial increase in general and administrative expenses to $46.3 million for Q3 2025, up from $23.3 million for Q3 2024.
• Dilution from net proceeds of $651.4 million from a public offering and $185.5 million from the sale of common stock, contributing to an increase in weighted-average shares outstanding.

Risks

• Uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally.
• Conditions to the closing of the Novartis acquisition and SpinCo separation may not be satisfied on the expected timetable or at all.
• Expected benefits or synergies from the Transactions may not be achieved in the expected timeframe, or at all.
• Risks and costs related to the implementation of the separation of SpinCo, including the ability to complete the separation in the anticipated timeframe, or at all.
• Changes to the configuration of the businesses included in the separation if implemented.
• The sale of certain of SpinCo's assets pursuant to a third-party right of first negotiation.
• The risk that competing offers or acquisition proposals will be made.
• The effects of disruption from the Transactions and the impact of the announcement and pendency on Avidity's and Novartis's businesses, including relationships with employees, business partners, or governmental entities.
• The risk that the Transactions may be more expensive to complete than anticipated.
• The risk that stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification, and liability.
• A diversion of management's attention from ongoing business operations and opportunities as a result of the Transactions or otherwise.
• No guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.
• No guarantee that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value.

Future Outlook

The company expects the Novartis acquisition to close in the first half of 2026, following the separation of its early-stage precision cardiology programs into a new public company, SpinCo. A Biologics License Application (BLA) submission for del-zota is planned for 2026 for accelerated approval. Topline data from the Phase 1/2 MARINA trial for del-desiran is expected in Q4 2025, with 54-week topline data from the Phase 3 HARBOR study anticipated in H2 2026. Topline data from the FORTITUDE biomarker cohort for del-brax is expected in Q2 2026, and Phase 3 FORTITUDE-3 readout and global regulatory submissions for del-brax are expected in 2028. The company's current cash position is projected to fund operations until mid-2028.

Management Comments

• Sarah Boyce, president and chief executive officer, stated: "In October, we announced that Avidity entered into a definitive merger agreement with Novartis, which we believe maximizes value for our investors, accelerates the global reach of our innovative neuroscience pipeline, and advances even more possibilities for our innovative science."
• Sarah Boyce also commented: "This important transaction, alongside compelling del-zota data and a successful pre-BLA meeting with the FDA in the third quarter, underscores the remarkable consistency of our AOC platform and the significant potential of del-zota, del-desiran, and del-brax to transform outcomes for people living with serious rare diseases."
• Sarah Boyce further noted: "These achievements are possible because of our incredibly talented Avidity team and the close collaboration of the dedicated patient and clinical communities we serve."

Industry Context

The acquisition of Avidity Biosciences by Novartis highlights the pharmaceutical industry's ongoing interest in innovative RNA therapeutics and targeted delivery platforms, particularly for rare diseases with high unmet medical needs. The spin-off of early-stage cardiology programs into a new public company (SpinCo) is a strategic move to unlock value for distinct asset classes, a common practice in biotech to focus resources and attract specialized investment. The positive clinical data for del-zota and its Breakthrough Therapy designation underscore the potential of Antibody Oligonucleate Conjugates (AOCs) to address previously untreatable conditions, positioning Avidity (and its acquired pipeline) at the forefront of precision medicine for neuromuscular disorders.

Comparison to Industry Standards

• The approximately $12 billion acquisition by Novartis is a significant valuation for a biopharmaceutical company, reflecting the high potential of Avidity's AOC platform and late-stage pipeline, particularly in rare disease indications. This valuation is comparable to other major acquisitions in the rare disease and gene therapy space, where novel platforms and advanced clinical assets command premium prices.
• The FDA's Breakthrough Therapy designation for del-zota for DMD is a strong indicator of its potential to offer substantial improvement over existing therapies, aligning with the industry's push for accelerated development of transformative treatments for severe, life-threatening conditions. This designation is typically granted to therapies that have demonstrated preliminary clinical evidence of substantial improvement over available therapies on clinically significant endpoints.
• The successful targeted delivery of RNA into muscle, as demonstrated by Avidity's AOC platform, represents a significant advancement in the field, addressing a long-standing challenge in oligonucleotide therapy delivery. This achievement sets a new benchmark for targeted RNA delivery, differentiating Avidity from competitors relying on less specific or less efficient delivery mechanisms.

Management Changes

Corporate Governance

Legal Proceedings

• The risk that stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• **Shareholders**: Significant positive impact due to the approximately $12 billion acquisition by Novartis, maximizing value. Shareholders will also receive shares in SpinCo, providing continued exposure to early-stage cardiology assets.
• **Employees**: Potential changes in employment structure and leadership for those moving to SpinCo or integrating into Novartis. Key leadership roles for SpinCo have been announced.
• **Patients**: Accelerated global reach of Avidity's neuroscience pipeline under Novartis, potentially bringing innovative RNA therapeutics to more people living with serious rare diseases faster. Continued progress in DMD, DM1, and FSHD programs is expected.
• **Partners (Eli Lilly, Bristol Myers Squibb)**: Continued collaboration revenue and potential for further milestones from existing agreements.
• **Regulatory Authorities (FDA)**: Continued engagement for BLA submissions and regulatory approvals for pipeline candidates.

Next Steps

• Separation of Avidity's early-stage precision cardiology programs into SpinCo.
• Closing of the Novartis acquisition in the first half of 2026.
• Publication of data analyses from the completed Phase 1/2 MARINA trial in Q4 2025.
• BLA submission for del-zota planned for 2026 for accelerated approval.
• Topline data from FORTITUDE biomarker cohort for del-brax expected in Q2 2026.
• 54-week topline data readout from global Phase 3 HARBOR study expected in H2 2026.
• Initiation of global, confirmatory Phase 3 study, FORTITUDE-3, for del-brax.
• Phase 3 FORTITUDE-3 readout and global regulatory submissions for del-brax expected in 2028.
• Filing of preliminary and definitive proxy statement with the SEC by Avidity for stockholder approval of the Transactions.

Key Dates

Recommendation

The definitive merger agreement with Novartis at a substantial $12 billion valuation represents a significant premium and a clear exit strategy for investors, maximizing shareholder value. The positive clinical data for del-zota, coupled with FDA Breakthrough Therapy designation and a clear regulatory path, de-risks a major pipeline asset. The spin-off of early-stage cardiology programs into a new public company (SpinCo) provides additional value creation opportunities for shareholders. While operating expenses have increased, this is typical for a biotech advancing multiple late-stage programs and is overshadowed by the acquisition news and strong clinical progress.

Keywords

Avidity Biosciences, Novartis acquisition, RNA therapeutics, Antibody Oligonucleotide Conjugates, AOCs, Duchenne muscular dystrophy, DMD, del-zota, myotonic dystrophy type 1, DM1, del-desiran, facioscapulohumeral muscular dystrophy, FSHD, del-brax, Biopharmaceutical, Clinical trials, FDA Breakthrough Therapy, SpinCo, Merger agreement, Q3 2025 financial results